Overview: Ganglioside GQ1b IgG TestIntroduction: The Ganglioside GQ1b IgG Test detects IgG antibodies to GQ1b to diagnose Miller Fisher syndrome, causing eye movement issues or weakness. Following 2023 AAN guidelines, it uses an immunoassay for high sensitivity, aiding in autoimmune screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in immunology for patients with suspected Miller Fisher syndrome.
Other Names: GQ1b IgG Assay, Anti-GQ1b IgG Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: GQ1b antibody testing began in the 1990s with Miller Fisher syndrome research. Immunoassays emerged in the 2000s, improving accuracy for autoimmune disorders.
Purpose: Diagnoses Miller Fisher syndrome, guides treatment, and monitors GQ1b IgG antibodies in patients with eye movement issues or weakness.
Test Parameters: 1. GQ1b IgG
Pretest Condition: No fasting required. Collect serum, CSF, or saliva at any time. Report symptoms like eye movement issues or weakness, and list medications.
Specimen: 2-5 mL serum (SST), 1-2 mL CSF (sterile container), or 1-2 mL saliva (sterile container). Centrifuge serum within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document eye movement issues, weakness, or history of Miller Fisher syndrome. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for autoimmune therapy.
Procedural Considerations: Uses an immunoassay to detect GQ1b IgG antibodies. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Hemolysis or improper storage can affect results. Other autoimmune conditions may cause cross-reactivity.
Clinical Significance: Positive GQ1b IgG antibodies suggest Miller Fisher syndrome, prompting treatment. Negative results may require further testing.
Specialist Consultation: Consult a neurologist for result interpretation.
Additional Supporting Tests: EMG, nerve conduction studies, or other ganglioside tests to confirm Miller Fisher syndrome.
Test Limitations: False positives may occur in other neurological conditions. Results require clinical correlation.
References: AAN GBS Guidelines, 2023; Neurology, Willison HJ, 2022.
